JACOBIO-B (1167.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Yinxiang Wang | Executive Chairman & CEO | 3.12M | -- | 1965 |
| Ms. Xiaojie Wang | Executive Director & President of Administration | 2.48M | -- | 1965 |
| Ms. Yunyan Hu | Executive VP & Executive Director | 2.66M | -- | 1962 |
| Ms. Tao Yang | Vice President of Human Resources | -- | -- | -- |
| Dr. Andrea Wang-Gillam M.D., Ph.D. | Executive VP, Chief Medical Officer and Global Head of R&D | -- | -- | 1971 |
| Ms. Yanping Wang | Executive Vice President of Non-Clinical R&D | -- | -- | -- |
| Dr. Haijun Wang | Senior Vice President of Information & Data Management | -- | -- | -- |
| Ms. Yuli Ding | Executive Vice President of Clinical Development | -- | -- | -- |
| Ms. Qing Xue | Joint Company Secretary | -- | -- | 1989 |
| Mr. Ming Fai Chung C.P.A. | Joint Company Secretary | -- | -- | 1979 |
JACOBIO-B
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 257
Description
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under multiple stage studies for indications such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73, a Pan-KRAS inhibitor for indications including NSCLC, PDAC, CRC, and other solid tumors; JAV-8263, a BET inhibitor for solid and liquid tumors; JAB-2485 Aurora A inhibitor, JAB-30355 P53 Y220C inhibitor, JAB-BX102 CD73 mAb inhibitor, JAB-26766 PARP 7 inhibitor, and JAB-BX300 LIF inhibitor under trials for solid tumor indications; and JAB-24114, a glutamine-utilizing enzyme for solid tumor and hematological malignancy indications. The company also develops IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. It has a collaboration agreement with Merck for cetuximab for combination trials. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
Corporate Governance
Upcoming Events
March 19, 2025 at 1:42 PM UTC
JACOBIO-B Earnings Date
Recent Events
Recent Events Information Not Available